-
Sreenath
Sharma,
D.
Bell,
J.
Settleman,
D.
Haber
(2007)
Epidermal growth factor receptor mutations in lung cancer
Nature Reviews Cancer, 7
-
JS
Lee,
V
Hirsh,
K
Park
(2012)
Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)
J Clin Oncol, 30
-
K.
Frank‐Raue,
S.
Rondot,
F.
Raue
(2010)
Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC
Molecular and Cellular Endocrinology, 322
-
Jimi
Yoon,
C.
Oh,
C.
Kim
(2011)
Stevens-Johnson Syndrome Induced by Vandetanib
Annals of Dermatology, 23
-
“ News and Events . ” FDA Approves New Treatment for Rare Form of Thyroid Cancer . FDA [ Apr 6 , 2011 ] . Web [ Feb 27 , 2012 ]
-
R.
Natale,
S.
Thongprasert,
F.
Greco,
Michael
Thomas,
C.
Tsai,
P.
Sunpaweravong,
D.
Ferry,
C.
Mulatero,
R.
Whorf,
J.
Thompson,
F.
Barlesi,
P.
Langmuir,
S.
Gogov,
J.
Rowbottom,
G.
Goss
(2011)
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
-
S
Leboulleux,
L
Bastholt,
TM
Krause
(2010)
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind phase II trial
Ann Oncol, 21
-
S.
Wells,
J.
Gosnell,
R.
Gagel,
J.
Moley,
D.
Pfister,
J.
Sosa,
M.
Skinner,
A.
Krebs,
J.
Vasselli,
M.
Schlumberger
(2010)
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 5
-
Susan
Pitt,
Herb
Chen
(2008)
The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer.
Surgery, 144 5
-
A.
Matuszczyk,
S.
Petersenn,
A.
Bockisch,
R.
Görges,
S.
Sheu,
P.
Veit,
K.
Mann
(2008)
Chemotherapy with Doxorubicin in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium
Hormone and Metabolic Research, 40
-
L.
Timmers,
J.
Beckeringh,
M.
Herk-Sukel,
E.
Boven,
J.
Hugtenburg
(2012)
Use and costs of oral anticancer agents in the Netherlands in the period 2000–2008
Pharmacoepidemiology and Drug Safety, 21
-
G.
Naumov,
M.
Nilsson,
T.
Cascone,
A.
Briggs,
O.
Straume,
L.
Akslen,
E.
Lifshits,
L.
Byers,
Li
Xu,
Hua-kang
Wu,
P.
Jänne,
Susumu
Kobayashi,
B.
Halmos,
D.
Tenen,
X.
Tang,
J.
Engelman,
B.
Yeap,
J.
Folkman,
B.
Johnson,
J.
Heymach
(2009)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
Clinical Cancer Research, 15
-
News and Events
FDA Approves New Treatment for Rare Form of Thyroid Cancer
-
S
Leboulleux,
E
Baudin,
JP
Travagli,
M
Schlumberger
(2004)
Medullary thyroid carcinoma
Clinical Endocrinology, 61
-
S.
Sarkar,
A.
Mazumdar,
R.
Dash,
D.
Sarkar,
P.
Fisher,
M.
Mandal
(2011)
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells
Journal of Cellular Physiology, 226
-
K.
Boér,
I.
Láng,
A.
Llombart-Cussac,
I.
Andreasson,
G.
Vivanco,
N.
Sanders,
G.
Pover,
E.
Murray
(2012)
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
Investigational New Drugs, 30
-
D.
Vitagliano,
V.
Falco,
Anna
Tamburrino,
S.
Coluzzi,
G.
Troncone,
G.
Chiappetta,
F.
Ciardiello,
G.
Tortora,
J.
Fagin,
A.
Ryan,
F.
Carlomagno,
M.
Santoro
(2010)
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Endocrine-related cancer, 18 1
-
F.
Ciardiello,
R.
Bianco,
R.
Caputo,
R.
Caputo,
V.
Damiano,
T.
Troiani,
D.
Melisi,
F.
Vita,
S.
Placido,
A.
Bianco,
G.
Tortora
(2004)
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Clinical Cancer Research, 10
-
S.
Leboulleux,
L.
Bastholt,
T.
Krause,
C.
Fouchardière,
J.
Tennvall,
A.
Awada,
J.
Gomez,
A.
Carrasco,
M.
Licour,
M.
Schlumberger
(2010)
Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial
Annals of Oncology, 21
-
R.
Boer,
O.
Arrieta,
Chih‐Hsin
Yang,
M.
Gottfried,
Valorie
Chan,
J.
Raats,
F.
Marinis,
R.
Abratt,
J.
Wolf,
F.
Blackhall,
P.
Langmuir,
T.
Milenkova,
Jessica
Read,
J.
Vansteenkiste
(2011)
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
-
P.
Runeberg-Roos,
M.
Saarma
(2007)
Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases
Annals of Medicine, 39
-
Clinical Medicine Insights: Oncology
-
Perikala
Kumar,
Hussein
Hodjati,
A.
Monabati,
A.
Talei
(2000)
Medullary Thyroid Carcinoma
Acta Cytologica, 44
-
M.
Lodish,
C.
Stratakis
(2008)
RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer
Expert Review of Anticancer Therapy, 8
-
F.
Ciardiello,
R.
Caputo,
V.
Damiano,
R.
Caputo,
T.
Troiani,
D.
Vitagliano,
F.
Carlomagno,
B.
Veneziani,
G.
Fontanini,
A.
Bianco,
G.
Tortora
(2003)
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Clinical cancer research : an official journal of the American Association for Cancer Research, 9 4
-
E.
Modigliani,
R.
Cohen,
J.
Campos,
B.
Conte‐Devolx,
B.
Maes,
A.
Boneu,
M.
Schlumberger,
J.
Bigorgne,
P.
Dumontier,
L.
Leclerc,
B.
Corcuff,
I.
Guilhem
(1998)
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.
Clinical endocrinology, 48 3
-
Maria
Nocera,
Eric
Baudin,
G.
Pellegriti,
AF
Cailleux,
C.
Mechelany-Corone,
M.
Schlumberger
(1995)
Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine
British Journal of Cancer, 83
-
A.
Tsao
(2012)
Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
Yearbook of Oncology, 2012
-
Dae-Ho
Lee,
G.
Lee,
S.
Kong,
M.
Kook,
S.
Yang,
S.
Park,
S.
Park,
B.
Keam,
D.
Park,
B.
Cho,
S.
Kim,
K.
Chung,
E.
Lee,
S.
Kim
(2006)
Epidermal growth factor receptor status in anaplastic thyroid carcinoma
Journal of Clinical Pathology, 60
-
Paul
Martin,
S.
Oliver,
S.
Kennedy,
E.
Partridge,
M.
Hutchison,
D.
Clarke,
P.
Giles
(2012)
Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Clinical therapeutics, 34 1
-
Li
Zhang,
Su
Li,
Yang
Zhang,
Jing
Zhan,
B.
Zou,
Robert
Smith,
Paul
Martin,
Yinrui
Jiang,
H.
Liao,
Z.
Guan
(2011)
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Clinical therapeutics, 33 3
-
P.
Saletti,
C.
Sessa,
S.
Dosso,
T.
Cerny,
V.
Renggli,
D.
Koeberle
(2011)
Phase I Dose-Finding Study of Vandetanib in Combination with Gemcitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Oncology, 81
-
Marco
PIEROTrIt,
Massimo
SANTOROt,
Robert
Jenkins,
Gabriella
SOZZIt,
Italia
BONGARZONEt,
Michele
GRIECOt,
Nicoletta
MONZINIt,
Monica
MIOZZOt,
Marie
Herrmann,
Alfredo
Fusco,
Ian
Hay,
And
PORTAt,
Giancarlo
Vecchiot
(1992)
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.
Proceedings of the National Academy of Sciences of the United States of America, 89
-
A.
Weil,
Paul
Martin,
Robert
Smith,
S.
Oliver,
P.
Langmuir,
Jessica
Read,
K.
Molz
(2010)
Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment
Clinical Pharmacokinetics, 49
-
R.
Natale,
D.
Bodkin,
R.
Govindan,
B.
Sleckman,
N.
Rizvi,
A.
Capó,
P.
Germonpré,
W.
Eberhardt,
P.
Stockman,
S.
Kennedy,
M.
Ranson
(2009)
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15
-
K.
Miller,
J.
Trigo,
C.
Wheeler,
A.
Barge,
J.
Rowbottom,
G.
Sledge,
J.
Baselga
(2005)
A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer
Clinical Cancer Research, 11
-
S.
Roman,
Rong
Lin,
J.
Sosa
(2006)
Prognosis of medullary thyroid carcinoma
Cancer, 107
-
T.
Tamura,
H.
Minami,
Y.
Yamada,
N.
Yamamoto,
T.
Shimoyama,
H.
Murakami,
A.
Horiike,
Y.
Fujisaka,
T.
Shinkai,
M.
Tahara,
K.
Kawada,
H.
Ebi,
Y.
Sasaki,
Haiyi
Jiang,
N.
Saijo
(2006)
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors
Journal of Thoracic Oncology, 1
-
H.
Ohgaki
(2005)
Genetic pathways to glioblastomas
Neuropathology, 25
-
Clarissa
Capp,
S.
Wajner,
D.
Siqueira,
Beatriz
Brasil,
L.
Meurer,
A.
Maia
(2010)
Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.
Thyroid : official journal of the American Thyroid Association, 20 8
-
S.
Leboulleux,
L.
Bastholt,
T.
Krause,
C.
Fouchardière,
J.
Tennvall,
A.
Awada,
J.
Gómez,
F.
Bonichon,
L.
Leenhardt,
C.
Soufflet,
M.
Licour,
M.
Schlumberger
(2012)
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
The Lancet. Oncology, 13 9
-
M.
Michael,
P.
Gibbs,
Robert
Smith,
A.
Godwood,
S.
Oliver,
N.
Tebbutt
(2009)
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
Investigational New Drugs, 27
-
S.
Duplomb,
Amandine
Benoit,
Laura
Mechtouff-Cimarelli,
T.
Cho,
O.
Derbel,
J.
Peix,
C.
Fouchardière
(2012)
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 2
-
H.
Verbeek,
M.
Alves,
J.
Groot,
J.
Osinga,
J.
Plukker,
T.
Links,
R.
Hofstra
(2011)
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
The Journal of clinical endocrinology and metabolism, 96 6
-
N.
Fersht,
L.
Vini,
R.
A’Hern,
C.
Harmer
(2001)
The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer.
Thyroid : official journal of the American Thyroid Association, 11 12
-
G.
Atalay,
F.
Cardoso,
A.
Awada,
M.
Piccart
(2003)
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 14 9
-
M.
Angrist,
S.
Bolk,
M.
Halushka,
P.
Lapchak,
A.
Chakravarti
(1996)
Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient
Nature Genetics, 14
-
C.
Rodríguez‐Antona,
J.
Pallarés,
C.
Montero‐Conde,
L.
Inglada-Perez,
E.
Castelblanco,
I.
Landa,
S.
Leskelä,
L.
Leandro-García,
E.
López-Jiménez,
R.
Letón,
A.
Cascón,
E.
Lerma,
M.
Martín,
M.
Carralero,
D.
Mauricio,
J.
Cigudosa,
X.
Matías-Guiu,
M.
Robledo
(2010)
Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
Endocrine-related cancer, 17 1
-
Paul
Martin,
S.
Oliver,
J.
Robertson,
S.
Kennedy,
Jessica
Read,
T.
Duvauchelle
(2011)
Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
Drugs in R&D, 11
-
E.
Modigliani,
R.
Cohen,
José
Campos,
B.
Conte‐Devolx,
B.
Maes,
A.
Boneu,
M.
Schlumberger,
J.
Bigorgne,
P.
Dumontier,
L.
Leclerc,
B.
Corcuff,
I.
Guilhem
(1998)
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients
Clinical Endocrinology, 48
-
S.
Holden,
S.
Eckhardt,
R.
Basser,
R.
Boer,
D.
Rischin,
Michael
Green,
M.
Rosenthal,
C.
Wheeler,
A.
Barge,
H.
Hurwitz
(2005)
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
Annals of oncology : official journal of the European Society for Medical Oncology, 16 8
-
E.
Cabebe,
G.
Fisher,
B.
Sikic
(2012)
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Investigational New Drugs, 30
-
R.
Herbst,
Yan
Sun,
W.
Eberhardt,
P.
Germonpré,
N.
Saijo,
Caicun
Zhou,
Jie
Wang,
Long-yun
Li,
F.
Kabbinavar,
Y.
Ichinose,
S.
Qin,
Li
Zhang,
B.
Biesma,
J.
Heymach,
P.
Langmuir,
S.
Kennedy,
H.
Tada,
B.
Johnson
(2010)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
The Lancet. Oncology, 11 7
-
S.
Wells,
B.
Robinson,
R.
Gagel,
H.
Dralle,
J.
Fagin,
M.
Santoro,
E.
Baudin,
R.
Elisei,
B.
Jarzab,
J.
Vasselli,
Jessica
Read,
P.
Langmuir,
A.
Ryan,
M.
Schlumberger
(2012)
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 2
-
C.
Blanke,
D.
Huse
(2010)
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors
Journal of Medical Economics, 13
-
A.
Rosen,
Shenhong
Wu,
Amelia
Damse,
E.
Sherman,
M.
Lacouture
(2012)
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
The Journal of clinical endocrinology and metabolism, 97 4
-
N.
Burnichon,
Laure
Vescovo,
L.
Amar,
R.
Libé,
A.
Reyniès,
A.
Vénisse,
E.
Jouanno,
I.
Laurendeau,
B.
Parfait,
J.
Bertherat,
P.
Plouin,
X.
Jeunemaître,
J.
Favier,
A.
Gimenez-Roqueplo
(2011)
Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.
Human molecular genetics, 20 20
-
F.
Carlomagno,
D.
Vitagliano,
T.
Guida,
F.
Ciardiello,
G.
Tortora,
G.
Vecchio,
A.
Ryan,
G.
Fontanini,
A.
Fusco,
M.
Santoro
(2002)
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Cancer research, 62 24
-
J.
Zang,
Shunquan
Wu,
Lei
Tang,
Xudong
Xu,
J.
Bai,
Caicui
Ding,
Yue
Chang,
Long
Yue,
En-Ming
Kang,
Jia
He
(2012)
Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis
PLoS ONE, 7
-
T.
Choueiri,
R.
Ross,
S.
Jacobus,
U.
Vaishampayan,
E.
Yu,
D.
Quinn,
N.
Hahn,
Thomas
Hutson,
G.
Sonpavde,
S.
Morrissey,
G.
Buckle,
William
Kim,
D.
Petrylak,
C.
Ryan,
M.
Eisenberger,
A.
Mortazavi,
G.
Bubley,
M.
Taplin,
J.
Rosenberg,
P.
Kantoff
(2012)
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 5
-
M.
Saunders,
R.
Wilson,
M.
Peeters,
Robert
Smith,
A.
Godwood,
S.
Oliver,
E.
Cutsem
(2009)
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study
Cancer Chemotherapy and Pharmacology, 64
-
Chiun
Hsu,
Tsai‐Sheng
Yang,
T.
Huo,
R.
Hsieh,
Chih-Wei
Yu,
W.
Hwang,
T.
Hsieh,
Wen‐Tsung
Huang,
Y.
Chao,
R.
Meng,
A.
Cheng
(2012)
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Journal of hepatology, 56 5
-
J.
Horti,
A.
Widmark,
A.
Stenzl,
M.
Federico,
R.
Abratt,
N.
Sanders,
G.
Pover,
I.
Bodrogi
(2009)
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
Cancer biotherapy & radiopharmaceuticals, 24 2
-
S.
Wedge,
D.
Ogilvie,
M.
Dukes,
J.
Kendrew,
R.
Chester,
J.
Jackson,
S.
Boffey,
P.
Valentine,
J.
Curwen,
H.
Musgrove,
G.
Graham,
G.
Hughes,
Andrew
Thomas,
E.
Stokes,
B.
Curry,
Graham
Richmond,
P.
Wadsworth,
Alison
Bigley,
L.
Hennequin
(2002)
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Cancer research, 62 16
-
Bing-Kun
Chen,
Yuji
Ohtsuki,
M.
Furihata,
T.
Takeuchi,
Jun
Iwata,
Sheng-Ben
Liang,
Hiroshi
Sonobe
(1999)
Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage.
International journal of oncology, 15 5
-
S.
Nicholson,
Janet
Peterson,
B.
Yektashenas
(2012)
Risk Evaluation and Mitigation Strategies (REMS)
Drug Safety, 35
-
M.
Dottorini,
A.
Assi,
M.
Sironi,
G.
Sangalli,
G.
Spreafico,
Luigia
Colombo
(1996)
Multivariate analysis of patients with medullary thyroid carcinoma: Prognostic significance and impact on treatment of clinical and pathologic variables
Cancer, 77
-
D.
Hanahan,
R.
Weinberg
(2011)
Hallmarks of Cancer: The Next Generation
Cell, 144
-
Edward
Kim,
F.
Khuri,
R.
Herbst
(2001)
Epidermal growth factor receptor biology (IMC-C225)
Current Opinion in Oncology, 13
-
B.
Robinson,
L.
Paz-Ares,
A.
Krebs,
J.
Vasselli,
R.
Haddad
(2010)
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
The Journal of clinical endocrinology and metabolism, 95 6